Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

Emergo Therapeutics

Status and phase

Completed

Phase 2

Conditions

Influenza -Like Illness

Influenza

Treatments

Drug: Placebo

Drug: Norketotifen

Study type

Interventional

Funder types

Industry

Identifiers

NCT04610047

NKT-203

Details and patient eligibility

About

This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.

Enrollment

315 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Able to understand the study and comply with all study procedures, and willing to provide written informed consent prior to the pre-dose examinations
Symptoms of ILI including all of the following:
- Fever ≥38º Celsius (oral)
- At least one of the following general systemic symptoms associated with ILI are present with a severity of moderate or greater: headache, feverishness or chills, muscle or joint pain, fatigue
- At least one of the following respiratory symptoms associated with ILI are present with a severity of moderate or greater: cough, sore throat, nasal congestion
Total symptom severity score (sum of the scores of all 7 individual symptoms) of ≥11 in the predose examinations
The time interval between the onset of symptoms and the predose examinations is ≤48 hours.
Females of childbearing potential and males agree to use an appropriate method of contraception as detailed in the protocol

Exclusion criteria

Known or suspected infection with Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) or Coronavirus Disease 2019 (COVID-19) illness
Female subjects who are pregnant, 2 weeks post-partum, or breastfeeding
Severe ILI requiring inpatient treatment
Any of the following risk factors (according to the CDC's list of People at High Risk for Developing Serious Flu-Related Complications):
- Extreme obesity (body mass index ≥40 kg/m^2)
- Residents of nursing homes or other long-term care facilities
- American Indians and Alaska natives
- Asthma
- Chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
- Neurological and neurodevelopmental conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
- Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease)
- Blood disorders (such as sickle cell disease)
- Endocrine disorders (such as diabetes mellitus)
- Kidney disorders
- Liver disorders
- Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
- Compromised immune system due to disease or medication (such as subjects with human immunodeficiency virus or cancer, or those on chronic steroids)
Presence of any severe or uncontrolled medical or psychiatric illness
History of or current autoimmune disease
History of recurrent lower respiratory tract infection
Any concurrent infection requiring systemic antimicrobial and/or antiviral therapy
Any clinically significant electrocardiogram (ECG) test
Received baloxavir, oseltamivir, peramivir, zanamivir, rimantadine, or amantadine within 30 days prior to the predose examinations
Received an investigational monoclonal antibody for a viral disease in the last year prior to the predose examinations
Received ketotifen fumarate, cromolyn sodium, or nedocromil sodium by any route of administration within 30 days prior to the predose examinations
Exposure to an investigational drug within 30 days prior to the predose examinations
History of allergic reaction to ketotifen
Any prior exposure to norketotifen